Each 5 ml contains: Sucralfate 500 mg.
Sucralfate is a complex formed from Sucrose Octasulphate and Polyaluminum hydroxide. Its anti-ulcer activity is the result of ulcer-adherent protein-Sucralfate complex that covers the ulcers site and protects it against further attack of acid, pepsin, and bile salts.
Laboratory and clinical studies indicate that Sucralfate may promote the healing of peptic ulcers in 3 ways: 1. Forming a chemical complex that binds to the ulcer site to establish a protective barrier.
2. Inhibits the actions of acid, pepsin, and bile.
3. Blocking the diffusion of gastric acid through the barrier of Sucralfate-Albumin.
Studies indicate that Sucralfate remains in the GI tract for extended periods, prolonging the therapeutic actions of the drug. Furthermore, Sucralfate is minimally absorbed from the GI tract which results insignificant side effects.
Short-term treatment (up to 8 weeks) of duodenal ulcer.
Usual adult dose: 10 ml (according to the mark on the measuring cup), four times a day, on empty stomach (1 hour before meal and at bedtime).
Therapy should be continued unless healing has been demonstrated by endoscopic or X-Ray examination.
There are no known contraindications to the use of Sucralfate.
This drug should be administered with caution in chronic renal failure and dialysis patients.
This drug should only be used during pregnancy if clearly needed.
This drug should be administered with caution in lactating women.
If required, antacids may be administered half an hour before or after administration of this drug.
Safety and effectiveness in children have not been established.
This drug should only be used during pregnancy if clearly needed.
This drug should be administered with caution in lactating women.
Adverse reactions of Sucralfate were minor and only rarely led to discontinuation of the drug. Constipation and dryness of mouth were the more frequent complaint. Other adverse reactions were diarrhea, nausea, vomiting, gastric discomfort, flatulence, pruritus, skin rash, sleepiness, dizziness, back pain, and headache.
This drug may reduce the extent of absorption or bioavailability of Cimetidine, Ciprofloxacin, Digoxin, Ketoconazole, Norfloxacin, Phenytoin, Ranitidine, Tetracycline, and Theophylline; patients should be advised to take these drugs 2 hours before Sucralfate.
Store below 30°C.
Protect from light.
Do not freeze.
Should be used within 3 months after opening the bottle.
A02BX02 - sucralfate ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sucralbat oral susp 500 mg/5 mL
100 mL x 1's
Sign Out
